Rxcurve
Medicare Part B payment limits Effective October 1 – December 31, 2026 Posted by CMS September 17, 2026
HCPCS J8611 · per 2.5 MG

Oral methotrexate (jylamvo)

Products billed under this code include Jylamvo.

Payment limit per 2.5 MG, by effective quarter, 3Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J8611

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Jylamvo Shorla Oncology Inc. 81927-0204-01 48 $876.672

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $18.264 +$1.797 2.5 MG Oral methotrexate (jylamvo) v1, posted September 17, 2026
3Q26 $16.467 −$2.243 2.5 MG Oral methotrexate (jylamvo) v1, posted September 15, 2026
2Q26 $18.71 +$0.069 2.5 MG Oral methotrexate (jylamvo) v1, posted September 15, 2026
1Q26 $18.641 +$0.175 2.5 MG Oral methotrexate (jylamvo) v1, posted September 15, 2026
4Q25 $18.466 −$0.062 2.5 MG Oral methotrexate (jylamvo) v1, posted September 8, 2026
3Q25 $18.528 – 2.5 MG Oral methotrexate (jylamvo) v1, posted March 10, 2026

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files